Tiered Pharmacy Copayments for Medications; Calendar Year 2020 Update, 11454-11455 [2020-03834]
Download as PDF
<![CDATA[
11454
Federal Register / Vol. 85, No. 39 / Thursday, February 27, 2020 / Notices
as possible, and at least five business
days prior to the event.
SUPPLEMENTARY INFORMATION:
Background: This is the third public
hearing the Commission will hold
during its 2020 report cycle. This
hearing will assess the intentions
behind China’s efforts to revise
international governance institutions,
norms and values, and technical
standards-setting bodies. It will examine
China’s vision for a revised global order,
its actions in existing and newlyestablished international organizations
to achieve its goals, and its attempts to
promote new norms for the global
digital economy. In so doing, the
hearing will attempt to identify whether
a distinguishable China model exists; if
so, to what extent China is seeking to
export it to other countries, and for what
purpose; and the consequences of
China’s growing influence in global
governance and standards-setting bodies
for U.S. interests. The hearing will be
co-chaired by Senator Carte Goodwin
and Senator Jim Talent. Any interested
party may file a written statement by
March 13, 2020 by mailing to the
contact above. A portion of each panel
will include a question and answer
period between the Commissioners and
the witnesses.
Authority: Congress created the U.S.China Economic and Security Review
Commission in 2000 in the National
Defense Authorization Act Pub. L. 106–
398), as amended by Division P of the
Consolidated Appropriations
Resolution, 2003 (Pub. L. 108–7), as
amended by Public Law 109–108
(November 22, 2005), as amended by
Public Law 113–291 (December 19,
2014).
Dated: February 24, 2020.
Daniel W. Peck,
Executive Director, U.S.-China Economic and
Security Review Commission.
[FR Doc. 2020–04035 Filed 2–26–20; 8:45 am]
BILLING CODE 1137–00–P
DEPARTMENT OF VETERANS
AFFAIRS
[OMB Control No. 2900–0178]
lotter on DSKBCFDHB2PROD with NOTICES
Agency Information Collection
Activity: Monthly Certification of OnThe-Job and Apprenticeship Training
Veterans Benefits
Administration, Department of Veterans
Affairs.
ACTION: Notice.
AGENCY:
Veterans Benefits
Administration, Department of Veterans
Affairs (VA), is announcing an
SUMMARY:
VerDate Sep<11>2014
17:26 Feb 26, 2020
Jkt 250001
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act (PRA) of
1995, Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
revision of a currently approved
collection, and allow 60 days for public
comment in response to the notice.
DATES: Written comments and
recommendations on the proposed
collection of information should be
received on or before April 27, 2020.
ADDRESSES: Submit written comments
on the collection of information through
Federal Docket Management System
(FDMS) at www.Regulations.gov or
Danny S. Green, VA Clearance Officer,
Office of Quality, Performance and Risk,
Veterans Benefit Administration,
Department of Veterans Affairs, 810
Vermont Avenue NW, Washington, DC
20420 or email to Danny.Green2@
va.gov. Please refer to ‘‘OMB Control
No. 2900–0178’’ in any correspondence.
During the comment period, comments
may be viewed online through FDMS.
FOR FURTHER INFORMATION CONTACT:
Danny S. Green at (202) 421–1354.
SUPPLEMENTARY INFORMATION: Under the
PRA of 1995, Federal agencies must
obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. This request for comment is
being made pursuant to Section
3506(c)(2)(A) of the PRA.
With respect to the following
collection of information, VBA invites
comments on: (1) Whether the proposed
collection of information is necessary
for the proper performance of VBA’s
functions, including whether the
information will have practical utility;
(2) the accuracy of VBA’s estimate of the
burden of the proposed collection of
information; (3) ways to enhance the
quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques or
the use of other forms of information
technology.
Authority: 38 U.S.C. 3680(c).
Title: Monthly Certification of OnThe-Job and Apprenticeship Training,
VA Form 22–6553d and VA Form 22–
6553d–1.
OMB Control Number: 2900–0178.
Type of Review: Revision of a
currently approved collection.
Abstract: Schools and training
establishments complete the form to
report whether the trainee’s number of
PO 00000
Frm 00125
Fmt 4703
Sfmt 4703
hours worked and/or to report the
trainee’s date of termination. VA Form
22–6553d–1 is an identical printed copy
of VA Form 22–6553d. VA Form 22–
6553d–1 is used when the computergenerated version of VA Form 22–6553d
is not available. VA uses the data
collected to process a trainee’s
educational benefit claim.
Affected Public: Private Sector.
Estimated Annual Burden: 5,693
hours.
Estimated Average Burden per
Respondent: 10 minutes.
Frequency of Response: On occasion
(9 responses per respondent annually).
Estimated Number of Respondents:
3,795 (34,155 responses).
By direction of the Secretary.
Danny S. Green,
VA Clearance Officer, Office of Quality,
Performance and Risk, Department of
Veterans Affairs.
[FR Doc. 2020–03905 Filed 2–26–20; 8:45 am]
BILLING CODE 8320–01–P
DEPARTMENT OF VETERANS
AFFAIRS
Tiered Pharmacy Copayments for
Medications; Calendar Year 2020
Update
Department of Veterans Affairs.
Notice.
AGENCY:
ACTION:
This Department of Veterans
Affairs (VA) Notice updates the
information on Tier 1 medications.
FOR FURTHER INFORMATION CONTACT:
Joseph Duran, Office of Community
Care (10D), Veterans Health
Administration (VHA), Department of
Veterans Affairs, Ptarmigan at Cherry
Creek, Denver, CO 80209;
Joseph.Duran2@va.gov; telephone: (303)
370–1637 (this is not a toll-free
number).
SUMMARY:
Section
17.110 of Title 38 CFR governs
copayments for medications that VA
provides to Veterans. Section 17.110
provides the methodologies for
establishing the copayment amount for
each 30-day or less supply of
medication provided by VA on an
outpatient basis (other than medication
administered during treatment).
Tier 1 medication means a multisource medication that has been
identified using the process described in
paragraph (b)(2) of this section. Not less
than once per year, VA will identify a
subset of multi-source medications as
Tier 1 medications. Only medications
that meet all of the criteria in 38 CFR
17.110(b)(2)(i), (ii), and (iii) will be
SUPPLEMENTARY INFORMATION:
E:\FR\FM\27FEN1.SGM
27FEN1
Federal Register / Vol. 85, No. 39 / Thursday, February 27, 2020 / Notices
eligible to be considered Tier 1
medications; and only those
medications that meet all of the criteria
in paragraph (b)(2)(i) of this section will
be assessed using the criteria in
paragraphs (b)(2)(ii) and (iii).
Based on the methodologies set forth
in § 17.110, this Notice updates the list
of Tier 1 medications for Calendar Year
2020. The Tier 1 medication list is
posted on VA’s Community Care
website at: https://www.va.gov/
COMMUNITYCARE/revenue_ops/
11455
copays.asp under the heading ‘‘Tier 1
Copay Medication List.’’
The following table is the Tier 1
Copay Medication List that is effective
January 1, 2020 and will remain in
effect until December 31, 2020.
Condition
VA product name
Arthritis and Pain .........................
Aspirin Buffered Tablet, Aspirin Chewable Tablet, Aspirin Enteric Coated Tablet, Allopurinol Tablet, Celecoxib
Capsule, Diclofenac Tablet, Ibuprofen Tablet, Meloxicam Tablet, Naproxen Tablet.
Clopidogrel Bisulfate Tablet, Warfarin Sodium Tablet.
Blood Thinners and Platelet Inhibitors.
Bone Health .................................
Cholesterol ..................................
Dementia .....................................
Diabetes ......................................
Dizziness (Vertigo) ......................
Electrolyte Supplement ...............
Gastrointestinal Health ................
Glaucoma and Eye Care .............
Heart Health and Blood Pressure
Mental Health ..............................
Respiratory Condition ..................
Seizures .......................................
Thyroid Conditions ......................
Urologic (Bladder and Prostate)
Health.
Alendronate Tablet.
Atorvastatin Tablet, Gemfibrozil Tablet, Lovastatin Tablet, Pravastatin Tablet, Rosuvastatin Calcium Tablet,
Simvastatin Tablet.
Donepezil Tablet.
Glimepiride Tablet, Glipizide Tablet, Metformin Hydrochloride (HCL) Tablet, Metformin HCL 24-hour Sustained Action (SA) Tablet, Pioglitazone HCL Tablet.
Meclizine HCL Tablet, Meclizine HCL Chewable Tablet.
Potassium SA Tablet, Potassium SA Dispersible Tablet.
Omeprazole Enteric Coated (EC) Capsule, Pantoprazole Sodium EC Capsule, Ranitidine Tablet.
Diclofenac 0.1% Solution, Dorzolamide 2%/Timolol 0.5% Solution, Latanoprost 0.005% Solution, PEG–400
0.4%/Propylene Glycol 0.3% Solution.
Amlodipine Tablet, Amiodarone HCL Tablet, Aspirin (see Arthritis and Pain), Atenolol Tablet, Benazepril Tablet, Carvedilol Tablet, Chlorthalidone Tablet, Clonidine Tablet, Diltiazem 24-hour Capsule, Diltiazem HCL
Tablet, Enalapril Maleate Tablet, Furosemide Tablet, Hydrochlorothiazide Capsule/Tablet,
Hydrochlorothiazide/Lisinopril Tablet, Hydrochlorothiazide/Losartan Tablet, Hydrochlorothiazide/Triamterene
Capsule/Tablet, Isosorbide Mononitrate SA Tablet, Lisinopril Tablet, Losartan Tablet, Metoprolol Succinate
SA Tablet, Metoprolol Tartrate Tablet, Nifedipine SA Tablet, Nitroglycerin Sublingual Tablet, Prazosin HCL
Capsule, Propranolol HCL Tablet, Spironolactone Tablet, Verapamil HCL Tablet, Verapamil HCL SA Tablet.
Amitriptyline HCL Tablet, Bupropion HCL Tablet, Bupropion HCL SA (12HR–SR) Tablet, Bupropion HCL SA
(24HR–XL) Tablet, Citalopram Hydrobromide Tablet, Duloxetine HCL EC Capsule, Escitalopram Oxalate
Tablet, Fluoxetine Capsule/Tablet, Lithium Carbonate Capsule/Tablet, Mirtazapine Tablet, Paroxetine HCL
Tablet, Sertraline HCL Tablet, Trazodone Tablet.
Montelukast NA Tablet.
Gabapentin Capsule/Tablet, Lamotrigine Tablet, Topiramate Tablet.
Levothyroxine Sodium Tablet.
Alfuzosin HCL SA Tablet, Doxazosin Mesylate Tablet, Finasteride Tablet, Sildenafil Tablet, Tamsulosin HCL
Capsule, Terazosin HCL Capsule.
Signing Authority
The Secretary of Veterans Affairs, or
designee, approved this document and
authorized the undersigned to sign and
submit the document to the Office of the
Federal Register for publication
electronically as an official document of
the Department of Veterans Affairs.
Pamela Powers, Chief of Staff,
Department of Veterans Affairs,
approved this document on February
19, 2020, for publication.
Luvenia Potts,
Regulation Development Coordinator, Office
of Regulation Policy & Management, Office
of the Secretary, Department of Veterans
Affairs.
[FR Doc. 2020–03834 Filed 2–26–20; 8:45 am]
lotter on DSKBCFDHB2PROD with NOTICES
BILLING CODE 8320–01–P
VerDate Sep<11>2014
17:26 Feb 26, 2020
Jkt 250001
PO 00000
Frm 00126
Fmt 4703
Sfmt 9990
E:\FR\FM\27FEN1.SGM
27FEN1
]]>Agencies
[Federal Register Volume 85, Number 39 (Thursday, February 27, 2020)]
[Notices]
[Pages 11454-11455]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03834]
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
Tiered Pharmacy Copayments for Medications; Calendar Year 2020
Update
AGENCY: Department of Veterans Affairs.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This Department of Veterans Affairs (VA) Notice updates the
information on Tier 1 medications.
FOR FURTHER INFORMATION CONTACT: Joseph Duran, Office of Community Care
(10D), Veterans Health Administration (VHA), Department of Veterans
Affairs, Ptarmigan at Cherry Creek, Denver, CO 80209;
[email protected]; telephone: (303) 370-1637 (this is not a toll-
free number).
SUPPLEMENTARY INFORMATION: Section 17.110 of Title 38 CFR governs
copayments for medications that VA provides to Veterans. Section 17.110
provides the methodologies for establishing the copayment amount for
each 30-day or less supply of medication provided by VA on an
outpatient basis (other than medication administered during treatment).
Tier 1 medication means a multi-source medication that has been
identified using the process described in paragraph (b)(2) of this
section. Not less than once per year, VA will identify a subset of
multi-source medications as Tier 1 medications. Only medications that
meet all of the criteria in 38 CFR 17.110(b)(2)(i), (ii), and (iii)
will be
[[Page 11455]]
eligible to be considered Tier 1 medications; and only those
medications that meet all of the criteria in paragraph (b)(2)(i) of
this section will be assessed using the criteria in paragraphs
(b)(2)(ii) and (iii).
Based on the methodologies set forth in Sec. 17.110, this Notice
updates the list of Tier 1 medications for Calendar Year 2020. The Tier
1 medication list is posted on VA's Community Care website at: https://www.va.gov/COMMUNITYCARE/revenue_ops/copays.asp under the heading
``Tier 1 Copay Medication List.''
The following table is the Tier 1 Copay Medication List that is
effective January 1, 2020 and will remain in effect until December 31,
2020.
------------------------------------------------------------------------
Condition VA product name
------------------------------------------------------------------------
Arthritis and Pain........................... Aspirin Buffered Tablet,
Aspirin Chewable Tablet,
Aspirin Enteric Coated
Tablet, Allopurinol
Tablet, Celecoxib
Capsule, Diclofenac
Tablet, Ibuprofen
Tablet, Meloxicam
Tablet, Naproxen Tablet.
Blood Thinners and Platelet Inhibitors....... Clopidogrel Bisulfate
Tablet, Warfarin Sodium
Tablet.
Bone Health.................................. Alendronate Tablet.
Cholesterol.................................. Atorvastatin Tablet,
Gemfibrozil Tablet,
Lovastatin Tablet,
Pravastatin Tablet,
Rosuvastatin Calcium
Tablet, Simvastatin
Tablet.
Dementia..................................... Donepezil Tablet.
Diabetes..................................... Glimepiride Tablet,
Glipizide Tablet,
Metformin Hydrochloride
(HCL) Tablet, Metformin
HCL 24-hour Sustained
Action (SA) Tablet,
Pioglitazone HCL Tablet.
Dizziness (Vertigo).......................... Meclizine HCL Tablet,
Meclizine HCL Chewable
Tablet.
Electrolyte Supplement....................... Potassium SA Tablet,
Potassium SA Dispersible
Tablet.
Gastrointestinal Health...................... Omeprazole Enteric Coated
(EC) Capsule,
Pantoprazole Sodium EC
Capsule, Ranitidine
Tablet.
Glaucoma and Eye Care........................ Diclofenac 0.1% Solution,
Dorzolamide 2%/Timolol
0.5% Solution,
Latanoprost 0.005%
Solution, PEG-400 0.4%/
Propylene Glycol 0.3%
Solution.
Heart Health and Blood Pressure.............. Amlodipine Tablet,
Amiodarone HCL Tablet,
Aspirin (see Arthritis
and Pain), Atenolol
Tablet, Benazepril
Tablet, Carvedilol
Tablet, Chlorthalidone
Tablet, Clonidine
Tablet, Diltiazem 24-
hour Capsule, Diltiazem
HCL Tablet, Enalapril
Maleate Tablet,
Furosemide Tablet,
Hydrochlorothiazide
Capsule/Tablet,
Hydrochlorothiazide/
Lisinopril Tablet,
Hydrochlorothiazide/
Losartan Tablet,
Hydrochlorothiazide/
Triamterene Capsule/
Tablet, Isosorbide
Mononitrate SA Tablet,
Lisinopril Tablet,
Losartan Tablet,
Metoprolol Succinate SA
Tablet, Metoprolol
Tartrate Tablet,
Nifedipine SA Tablet,
Nitroglycerin Sublingual
Tablet, Prazosin HCL
Capsule, Propranolol HCL
Tablet, Spironolactone
Tablet, Verapamil HCL
Tablet, Verapamil HCL SA
Tablet.
Mental Health................................ Amitriptyline HCL Tablet,
Bupropion HCL Tablet,
Bupropion HCL SA (12HR-
SR) Tablet, Bupropion
HCL SA (24HR-XL) Tablet,
Citalopram Hydrobromide
Tablet, Duloxetine HCL
EC Capsule, Escitalopram
Oxalate Tablet,
Fluoxetine Capsule/
Tablet, Lithium
Carbonate Capsule/
Tablet, Mirtazapine
Tablet, Paroxetine HCL
Tablet, Sertraline HCL
Tablet, Trazodone
Tablet.
Respiratory Condition........................ Montelukast NA Tablet.
Seizures..................................... Gabapentin Capsule/
Tablet, Lamotrigine
Tablet, Topiramate
Tablet.
Thyroid Conditions........................... Levothyroxine Sodium
Tablet.
Urologic (Bladder and Prostate) Health....... Alfuzosin HCL SA Tablet,
Doxazosin Mesylate
Tablet, Finasteride
Tablet, Sildenafil
Tablet, Tamsulosin HCL
Capsule, Terazosin HCL
Capsule.
------------------------------------------------------------------------
Signing Authority
The Secretary of Veterans Affairs, or designee, approved this
document and authorized the undersigned to sign and submit the document
to the Office of the Federal Register for publication electronically as
an official document of the Department of Veterans Affairs. Pamela
Powers, Chief of Staff, Department of Veterans Affairs, approved this
document on February 19, 2020, for publication.
Luvenia Potts,
Regulation Development Coordinator, Office of Regulation Policy &
Management, Office of the Secretary, Department of Veterans Affairs.
[FR Doc. 2020-03834 Filed 2-26-20; 8:45 am]
BILLING CODE 8320-01-P
